Transdermal Spray Developers See Opportunity for Improved Drug Delivery
Kenneth Kirby, the president of TransDermal Delivery Solutions Corp., sees his company?s transdermal drug delivery system as transforming the way we think about medication.
Could transdermal drug delivery really change the way we take our medicine? Kenneth Kirby, President of
By opting for transdermal delivery over oral delivery, Kirby says the drugs are better able to retain their potency and work factor. A potential downside would be the issue of restrictions on lifestyle activities, since users would be unable to get wet following application for fear of needing to reapply. However, Kirby says the company is working on that issue by adding ethanol to the spray to help it dry faster.
TransDermal Delivery Solutions, and majority-owned subsidiary, Hormone Replacement Technologies, are
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025